Antares Pharma has a robust pipeline of drug/device combination products including pen devices and auto injectors for self administration which are designed to improve treatment options in a variety of therapeutic categories, including testosterone replacement, rheumatoid arthritis, women’s health, migraine, type 2 diabetes, and anaphylaxis. Class leading device technology platforms, such as our Vibex, QuickShot, and pen device platforms, combined with safe and effective therapies have the potential to improve both patient outcomes and convenience with reliable, accurate, patient-friendly treatment options.
The start of the AndroGel court proceedings is a thorn in the side of AbbVie, which is facing a host of challenges to some of its biggest blockbusters. Sales of its top-selling arthritis remedy Humira did jump 23% year-over-year in the first quarter to $ billion, but the company is facing biosimilar competition overseas that’s hampering its growth, and biosimilars are on their way in the . Meanwhile, sales of its hepatitis C combo Viekira Pak fell 36% to $263 million during the quarter, as AbbVie struggles to compete for market share against Gilead Sciences’ Harvoni.